Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, ointments, injectables, creams, syrups, suppositories, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, pegylated liposome doxorubicin, etc.; antiritrovirals comprising lopinavir, indinavir, ritonavir, darunavir, zidovudine, lamivudin, and various combination therapy products; and products for other therapeutic areas, such as antibiotics, anti-fungals, anti-malarials, anti-virals, anti-manics, anti-convulsants, anti-migraines, anti-allergics, anthelmintics, anti-emetics, anti-inflammatory (NSAIDS), sedatives, cerebral activators, ulcer healing agents, laxatives, probiotics, dige
| Current Price | ₹58.94 |
|---|---|
| Market Cap | ₹15 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 28.9 |
| Return on Equity | 5.27% |
| 52-Week Range | ₹36.11 – ₹87.91 |
| Beta (1Y) | 1.31 |
1. Manufacturing Pharmaceutical Formulations-100%
Colinz Laboratories Ltd is trading at ₹58.94, with a market capitalisation of ₹15 Cr.
Colinz Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Colinz Laboratories Ltd has a P/E of 28.9 and a return on equity of 5.27%.